Core Viewpoint - The legal opinion letter confirms the legality of the procedures and results of Anhui Wanbang Pharmaceutical Technology Co., Ltd.'s second extraordinary general meeting of shareholders in 2025, ensuring compliance with relevant laws and regulations [2][4][6]. Group 1: Meeting Procedures - The second board meeting of the company on August 4, 2025, resolved to convene the extraordinary general meeting and published the notice detailing the time, location, and agenda [2]. - The meeting was conducted through a combination of on-site and online voting, with specific time slots for network voting provided [3]. - The meeting was chaired by the company's chairman, Ms. Tao Chunlei, and all procedural aspects were found to be consistent with the published notice [3][4]. Group 2: Attendance and Qualifications - A total of 63 shareholders attended the meeting, representing 41,659,550 shares, which accounted for 62.8712% of the total voting shares [4]. - The qualifications of the attendees and the convenor were verified and deemed compliant with the Company Law and relevant regulations [4][5]. Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online methods, with results being counted and announced immediately [5]. - The proposal to amend the company's articles of association received 41,547,550 votes in favor, representing 99.7312% of the valid votes [5][6]. - Other proposals, including the appointment of the auditing firm and the election of the board of directors, also passed with similar overwhelming support [6][7]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendance, and voting procedures, were in accordance with legal requirements, rendering the results valid [8].
万邦医药: 安徽承义律师事务所关于安徽万邦医药科技股份有限公司2025年第二次临时股东大会的法律意见书